Valneva, a French vaccine specialist, closed the week at 3.89 euros, marking a decline of 11.35%. This correction follows an annual increase of 64.61%, highlighting the characteristic volatility of the stock.
Valneva's stock recorded a decline of 11.35% over the past week, bringing the closing price to 3.89 euros. This contraction contrasts with a still largely positive annual performance, established at 64.61%, confirming investors' interest in the biotechnology company over an extended period. Over three months, the decline remains limited to 1.77%, suggesting a recent correction after a sustained upward phase.
The volatility remains high, with a one-month indicator at 17.56, indicating the amplitude of price fluctuations that the stock regularly experiences. This high volatility is inherent in the biotechnological sector, which is particularly sensitive to clinical results, regulatory publications, and market expectations. The annual evolution reflects a favorable dynamic, but the past week illustrates how quickly sentiment can change in such cases.
Technical Analysis of the Stock
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical standpoint, the stock shows a contrasting position. The 20-day moving average is at 4.17 euros, a level that the current price no longer defends, signaling short-term selling pressure. However, the 50-day (3.93 euros) and 200-day (3.59 euros) moving averages remain below the current price, illustrating a still constructive long-term trend.
The Relative Strength Index (RSI) stands at 41, a level that indicates a weakened momentum without yet reaching the traditional oversold zone located below 30. This decline in the RSI accompanies the weekly correction and reflects a short-term technical exhaustion. Moreover, the stock is now closer to its identified support at 2.39 euros than to its resistance at 5.09 euros, leaving little margin before a potential test of this key area if the downward movement continues.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
